FibroFind

FibroFind is a Newcastle, UK-based contract non-clinical testing organization specializing in fibrotic diseases. Combining years of research experience with proprietary technologies, FibroFind provides strong support for drug discovery and development.

This article will provide a detailed explanation of the company's service features and disease models.

Features of FibroFind's preclinical contract services

Proprietary human tissue slicing technology (PCTS)

One of FibroFind's key features is its Precision Cut Tissue Slices (PCTS) technology using human tissues. Unlike traditional cell cultures, it allows for drug evaluation while maintaining the complex environment found in living organisms.

This allows for more accurate prediction of human response prior to transfer to clinical trials. I believe that this technology will make a significant contribution to reducing development risks.

Extensive track record in fibrotic disease research

Our strengths include specialization in fibrotic diseases of the liver, kidneys, and lungs, backed by decades of research experience. Our team of experts, equipped with extensive knowledge, proposes study designs tailored to client needs.

Rather than simply acting as a contractor, we function as a partner in the drug discovery process. We have established a system that can strongly support research and development through the provision of reliable data.

An example of FibroFind's pathological model

Human liver PCTS (precision-cut liver sections)

This is a highly accurate slice model that retains the main structure and cellular environment of human liver tissue. It allows for evaluation of cell-cell interactions and the matrix environment, which are difficult to reproduce with conventional cell cultures, enabling data acquisition that reflects clinical-like responses in efficacy studies of novel drugs for liver fibrosis (such as NAFLD/NASH).

Kidney and lung fibrosis models

Human kidney and lung disease models that apply proven PCLS technology from the liver. They reproduce the fibrotic mechanisms in idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD), and are used to evaluate tissue responses to inflammation-inducing stimuli and the antifibrotic effects of standard therapeutic drugs.

FibroFind Non-clinical Case Studies

Drug Efficacy Evaluation Study of a Novel Antifibrotic Drug

This is a study to measure the anti-fibrotic effect of a compound under development by administering it to a human liver PCTS model. Comparisons with standard of care (SOC) drugs and confirmation of dose-dependency will be performed.

Because actual human tissues are used, we have a great deal of experience in obtaining predictive data that complement mouse models and are useful as a bridge to clinical practice.

Mechanism of action (MoA) elucidation and target exploration study

This is a test that analyzes the variations of specific genes and proteins using models of the kidneys and lungs. By combining techniques such as transcriptome analysis (RNA-seq), it is possible to precisely identify the pathways by which a drug inhibits fibrosis. This is utilized as a case in validating drug discovery targets.

FibroFind Company Information

FibroFind is a biotechnology company originating from Newcastle University in the UK. In 2025, with investment from Vespa Capital, it continues to grow as a global contract research organization combining many years of research achievements with a strong management foundation.

Our strength is that we combine the precision of a university laboratory level with the speed that industry demands. With pharmaceutical and biotech companies around the world as our clients, we operate globally.